JU
Jupiter Neurosciences, Inc.
JUNS · NASDAQ
$3.41 +9.29% (+$0.29)
1M -34.17%
Market Cap $1.65M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
3/9Valuation
0 /100
Expensive P/S 25.55x
PEG N/A
P/B N/A
Growth
0 /100
Declining Rev. growth 54.62%
FCF growth N/A
Book val. growth N/A
Profitability
20 /100
Weak Net margin 14,220.10%
Op. margin 15,166.70%
FCF margin 11,206.00%
Quality
0 /100
Poor ROA 247.39%
Asset turnover 0.02x
ROIC 709.40%
Debt
7 /100
High Int. coverage -262.75x
Current ratio 0.66x
Net debt/EBITDA N/A
Stability
4 /100
Unstable EPS volatility 126.84%
Profitable years 0
Beta 1.79x
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o JUNS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Christer Rosen
Employees
5
Headquarters
Jupiter
Nadchodzące wydarzenia
02 GRU
Earnings
Upcoming earnings report